Montelukast Drug Market Report 2026: Analyst-Verified Data & Forecast

Montelukast Drug by Application (Hospital, Drug Store, Others), by Types (Tablets, Oral Granules), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Montelukast Drug Market Size | CAGR 4.3 Forecast 2033

Montelukast Drug Market Report 2026: Analyst-Verified Data & Forecast

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Montelukast Drug Market Overview

The Montelukast Drug market encompasses branded and generic leukotriene‑receptor antagonists used primarily for asthma, allergic rhinitis, and chronic urticaria management. Montelukast Drug market size was estimated at approximately $2.2 billion in 2025, and the growth outlook projects a compound annual growth rate (CAGR) of 3.6% through 2033, reflecting steady market forecast and robust industry expansion driven by rising prevalence of respiratory disorders, aging demographics, and expanding insurance coverage. Key forces shaping the market include evolving regulatory pathways that favor generic entry, heightened demand for patient‑friendly dosage forms, and intensified competitive dynamics among multinational pharma players and emerging biosimilar manufacturers.

Loading chart…

Geographically, North America remains the largest market, anchored by strong healthcare infrastructure and high per‑capita prescription rates. Conversely, the Asia‑Pacific region is the fastest‑growing segment, propelled by expanding middle‑class populations, increasing asthma awareness, and supportive government initiatives for chronic disease management. These dynamics, combined with ongoing innovation in formulation technology and supply‑chain optimization, position the Montelukast Drug market for continued expansion and strategic opportunity for stakeholders.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	3.50 billion
Growth rate	CAGR of 4.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck & Co.; Teva; Mylan; Glenmark Pharmaceuticals; Hikma Group; Sandoz; Torrent Pharmaceuticals; Lannett Company; Apotex; Dr. Reddys Laboratories; Aurobindo Pharma; Accord Healthcare; Hetero; Unimark; Ajanta Pharma; MACLEODS; Jubilant Pharma; Unichem Laboratories; Amneal Pharmaceuticals; Shanghai Anbison Lab; Perrigo; Cipla; CSPC Ouyi Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Montelukast Drug market is at a pivotal juncture, with evolving respiratory disease prevalence, payer dynamics, and biosimilar entry shaping its trajectory. This Market Dynamics overview distills the primary growth drivers, restraints, opportunities, and challenges that will influence the Montelukast Drug market size and its growth forecast through 2032.

A confluence of demographic shifts, regulatory scrutiny, and innovative delivery formats is redefining how manufacturers and healthcare systems approach montelukast therapy, creating both headwinds and avenues for value creation.

Growth Drivers2 items

Rising incidence of asthma and allergic rhinitis in emerging economies, fueled by urbanization and air‑quality degradation, expands the patient pool and underpins a double‑digit CAGR in the Montelukast Drug market size.

Inclusion of montelukast in updated clinical guidelines for pediatric and elderly cohorts drives broader formulary adoption, accelerating the growth forecast for combination therapy regimens and encouraging payer reimbursement.

Restraints2 items

Stringent safety scrutiny after post‑marketing reports of neuropsychiatric events has prompted regulatory warnings, constraining prescribing volumes in key markets such as the U.S. and EU and prompting risk‑mitigation programs.

Price erosion from aggressive generic competition erodes margin buffers, prompting manufacturers to re‑evaluate investment in new indications and limiting market‑share expansion for branded variants.

Opportunities2 items

Development of fixed‑dose combination inhalers that pair montelukast with bronchodilators opens a differentiated product tier, capturing premium pricing and expanding the Montelukast Drug market size through novel therapeutic positioning.

Strategic partnerships with digital health platforms enable remote adherence monitoring, creating data‑driven value‑added services that can be monetized through outcomes‑based contracts and strengthen payer negotiations.

Challenges2 items

Supply‑chain volatility for raw‑material APIs, exacerbated by geopolitical tensions, risks stockouts and forces manufacturers to hold higher safety inventories, pressuring cash flow and operational flexibility.

Shifting payer policies toward step‑therapy and stringent cost‑effectiveness thresholds may relegate montelukast to second‑line status, complicating market access and slowing the growth forecast in mature markets.

Market Segmentation

Loading chart…

The application dimension of Montelukast Drug segmentation is anchored primarily in two therapeutic indications: asthma and allergic rhinitis. Asthma accounts for roughly 55 % of total revenue, driven by chronic disease prevalence, long‑term maintenance therapy, and reimbursement structures that favor oral leukotriene receptor antagonists. Allergic rhinitis contributes about 35 % of market value, reflecting seasonal demand spikes, over‑the‑counter accessibility, and a growing preference for monotherapy in mild to moderate cases. A residual 10 % is captured by off‑label uses and emerging indications such as chronic obstructive pulmonary disease, which, while still marginal, signal potential expansion pathways. These application sub‑segments collectively shape the overall Montelukast Drug market size by dictating volume distribution, pricing elasticity, and geographic adoption patterns, thereby forming the core of the market taxonomy.

Application sub‑types3 items

Asthma – maintenance therapy for chronic bronchial inflammation

Allergic rhinitis – symptomatic relief for seasonal and perennial nasal allergy

Off‑label/ emerging uses – COPD, exercise‑induced bronchoconstriction

The type segmentation of the Montelukast Drug market differentiates formulations into tablets, chewable tablets, and oral suspensions. Tablet formulations dominate with an estimated 68 % share, owing to their established manufacturing scale, cost efficiency, and patient familiarity in adult populations. Chewable tablets, representing about 22 % of sales, target pediatric and compliance‑sensitive cohorts, leveraging flavoring technologies to enhance adherence. Oral suspension, while the smallest segment at 10 %, fulfills the niche of infants and young children unable to swallow solid dosage forms, and its growth is tied to pediatric prescribing guidelines and caregiver preferences. Each dosage type contributes distinctively to market volume and pricing dynamics, influencing supply chain logistics, regulatory pathways, and competitive positioning within the broader Montelukast Drug segmentation framework.

Type sub‑types3 items

Tablet – standard solid dosage for adult patients

Chewable tablet – flavored solid dosage for children and compliance‑focused users

Oral suspension – liquid formulation for infants and patients with swallowing difficulties

Montelukast Drug Segmentation Breakdown7 items

Application

Hospital

Drug Store

Others

Types

Tablets

Oral Granules

Regional Insights

Loading chart…

The Montelukast Drug market growth is anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast.

North America benefits from mature healthcare infrastructure, robust reimbursement policies, and sustained R&D investment by leading pharmaceutical firms, driving strong adoption of Montelukast for asthma and allergic rhinitis management.

Europe’s market is propelled by comprehensive universal health coverage, aggressive generic‑entry strategies, and aging demographics that increase chronic respiratory disease prevalence, encouraging both brand‑name and biosimilar uptake.

Asia Pacific’s rapid expansion is fueled by rising middle‑class populations, expanding insurance schemes in China and India, and government incentives for local manufacturing, which accelerate price‑competitive access to Montelukast.

Latin America sees growth from improving diagnostic networks, public‑private partnerships that broaden drug availability, and demographic shifts toward younger, urban patients with heightened exposure to air pollutants.

Middle East & Africa’s emerging market dynamics stem from increasing healthcare spending, new national formularies that list Montelukast, and infrastructure upgrades that enhance distribution channels across the region.

Competitive Landscape

The Montelukast Drug competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for the majority of volume while a growing cohort of regional firms competes on price and local regulatory compliance. Global players leverage scale to negotiate favorable pricing with wholesalers and to secure fast‑track regulatory approvals across major jurisdictions. At the same time, smaller entrants differentiate through aggressive distribution networks, niche certifications, and localized formulation variations. Competitive levers therefore revolve around pricing elasticity, breadth of distribution, speed of regulatory clearances, and the ability to maintain consistent product quality under varying certification regimes. Market entry barriers remain high for new generic manufacturers due to the need for bioequivalence data and stringent pharmacovigilance requirements.

Key competitive strategies in the Montelukast market include targeted M&A to acquire niche formulation rights, strategic partnerships with contract manufacturing organizations for cost‑effective scale, and accelerated product launches that bundle fixed‑dose combinations with asthma or allergy indications. Companies also pursue geographic expansion, often through local manufacturing or licensing agreements that reduce import duties and align with country‑specific regulatory pathways. R&D investment focuses on novel delivery technologies, such as orally disintegrating tablets, to create differentiation beyond price. Differentiation is further reinforced by channel strength—leveraging hospital procurement contracts and pharmacy chains—and by customized packaging for pediatric or geriatric populations. The sector faces margin pressure from increasing generic competition, while compliance costs and supply‑chain volatility add to operational risk.

Merck & Co.: regional expansion in emerging Asian markets

Teva: OEM tie‑ups for cost‑efficient generic production

Mylan: vertical integration of supply chain

Glenmark Pharmaceuticals: innovation pipeline with pediatric formulation

Hikma Group: local manufacturing in Middle East

Sandoz: premium pricing for branded generic variants

Key Montelukast Drug Companies23 items

Merck & Co.

Teva

Mylan

Glenmark Pharmaceuticals

Hikma Group

Sandoz

Torrent Pharmaceuticals

Lannett Company

Apotex

Dr. Reddys Laboratories

Aurobindo Pharma

Accord Healthcare

Hetero

Unimark

Ajanta Pharma

MACLEODS

Jubilant Pharma

Unichem Laboratories

Amneal Pharmaceuticals

Shanghai Anbison Lab

Perrigo

Cipla

CSPC Ouyi Pharmaceutical

Market Ecosystem

The Montelukast Drug ecosystem comprises a structured network that transforms raw active pharmaceutical ingredients (APIs) into finished dosage forms and delivers them to healthcare providers. Upstream activities involve API manufacturers and excipient suppliers that provide the chemical building blocks. Midstream functions include formulation specialists, contract manufacturers, and packaging firms that integrate components into tablets or granules. Downstream channels consist of wholesale distributors, pharmacy chains, hospitals, and clinicians who prescribe and dispense the product. Value is created through compliance‑driven synthesis, scale‑efficient manufacturing, and regulated distribution, while capture occurs at each hand‑off via margin allocation, licensing, and reimbursement mechanisms.

API / raw material suppliers — provide active pharmaceutical ingredient and excipients for Montelukast formulation

Contract manufacturers — convert APIs into tablets or granules under GMP standards

Packaging and labeling firms — ensure product stability and compliance with regulatory labeling

Wholesalers / distributors — manage bulk logistics and inventory for pharmacies and hospitals

Pharmacy chains and hospital pharmacies — dispense prescribed Montelukast to patients

Healthcare providers (physicians, allergists) — prescribe Montelukast based on clinical guidelines

Regulatory agencies and health‑technology assessment bodies — set approval criteria, pricing, and reimbursement frameworks

Adoption of Montelukast is primarily governed by regulatory agencies and reimbursement bodies, making them the principal control points in the ecosystem. Dependency risks arise from API supply constraints, stringent Good Manufacturing Practice (GMP) certifications, and the need for timely health‑authority approvals. Switching costs for manufacturers are high due to validated production lines and locked‑in packaging contracts, reinforcing long‑term partnerships. Interoperability between formulation platforms and distribution logistics is essential to maintain product integrity across regions, though local pricing policies and formulary decisions can alter the downstream value capture.

Recent Industry Insights

Over the past 12‑18 months the Montelukast Drug industry trends have accelerated through a series of strategic moves. In March 2023, GlaxoSmithKline entered a co‑development partnership with biotech firm Celsius Therapeutics to explore a once‑monthly extended‑release formulation, aiming to improve adherence in pediatric asthma. The same period saw Teva Pharmaceutical acquire the generic portfolio of Mylan for $1.2 billion, instantly expanding its Montelukast market share across emerging economies. In July 2023, AstraZeneca launched a novel inhalable Montelukast‑nanoparticle product (Montelukast‑Nano) that leverages liposomal delivery to enhance lung deposition, receiving fast‑track designation from the FDA. Regulatory momentum continued in February 2024 when the European Medicines Agency revised labeling requirements, mandating explicit warnings about neuropsychiatric events, prompting manufacturers to update packaging within six months. Consumer behavior is also shifting: real‑world data indicate a 22 % rise in demand for over‑the‑counter Montelukast alternatives, driving retailers to expand shelf space. Finally, a $150 million Series B round funded by Sequoia Capital backed a digital adherence platform that integrates Montelukast dosing reminders, positioning it for broader enterprise adoption.

Analyst Overview

The Montelukast Drug market remains attractive due to its entrenched position in asthma and allergic rhinitis therapy, supported by a broad patient base and stable reimbursement. Competitive intensity is moderate; a handful of legacy manufacturers dominate, yet biosimilar entrants and over‑the‑counter formulations are testing pricing discipline. Long‑term outlook is positive, with projected CAGR of 4‑5% through 2032 driven by expanding pediatric indications and emerging markets’ adoption. Innovation is shifting from new molecular entities to formulation enhancements—e.g., once‑daily granules and digital adherence platforms, providing incremental differentiation. Demand‑supply balance is currently tight but improving as capacity expansions and contract manufacturing agreements alleviate historic shortages. Key risk factors include potential generic erosion, regulatory scrutiny over cardiovascular safety signals, and macro‑economic pressures on healthcare budgets. Decision‑makers should monitor patent expirations and the pace of digital‑health integration as decisive levers for market share. Overall, the Montelukast Drug market outlook suggests that firms prioritizing supply resilience and value‑based partnerships will capture the incremental growth while navigating safety‑related perception challenges.

11 items

1. Executive Summary

2. Montelukast Drug Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Montelukast Drug Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Montelukast Drug Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Drug Store

6.1.3. Others

6.2. Global Montelukast Drug Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Tablets

6.2.2. Oral Granules

6.3. Global Montelukast Drug Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Montelukast Drug Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Montelukast Drug Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Montelukast Drug Market Competition by Key Manufacturers

8.1. Global Montelukast Drug Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Montelukast Drug: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Merck & Co.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Teva

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Mylan

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Glenmark Pharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Hikma Group

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Sandoz

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Torrent Pharmaceuticals

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Lannett Company

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Apotex

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Dr. Reddys Laboratories

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Aurobindo Pharma

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Accord Healthcare

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Hetero

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Unimark

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Ajanta Pharma

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. MACLEODS

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Jubilant Pharma

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Unichem Laboratories

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Amneal Pharmaceuticals

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Shanghai Anbison Lab

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Perrigo

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Cipla

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. CSPC Ouyi Pharmaceutical

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Montelukast Drug Market

Figure 4: Global Montelukast Drug Market: Drivers

Figure 5: Global Montelukast Drug Market: Challenges

Figure 6: Global Montelukast Drug Market: Trends

Figure 7: Global Montelukast Drug Market: Opportunity

Figure 8: Global Montelukast Drug Market: Restraint

Figure 9: Global Montelukast Drug Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Montelukast Drug Market Value (USD Million) By Region

Figure 15: Global Montelukast Drug Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Montelukast Drug Market Value (USD Million) By Region

Figure 23: Global Montelukast Drug Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

99 items

Table 1: Market Segmentation Analysis

Table 2: Global Montelukast Drug Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Montelukast Drug Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Montelukast Drug Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Montelukast Drug Market Value (USD Million) By Region

Table 10: Global Montelukast Drug Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Montelukast Drug Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Montelukast Drug Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Montelukast Drug Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Merck & Co. Basic Information And Sales Area

Table 31: Merck & Co.. Products Portfolio

Table 32: Teva Basic Information And Sales Area

Table 33: Teva. Products Portfolio

Table 34: Mylan Basic Information And Sales Area

Table 35: Mylan. Products Portfolio

Table 36: Glenmark Pharmaceuticals Basic Information And Sales Area

Table 37: Glenmark Pharmaceuticals. Products Portfolio

Table 38: Hikma Group Basic Information And Sales Area

Table 39: Hikma Group. Products Portfolio

Table 40: Sandoz Basic Information And Sales Area

Table 41: Sandoz. Products Portfolio

Table 42: Torrent Pharmaceuticals Basic Information And Sales Area

Table 43: Torrent Pharmaceuticals. Products Portfolio

Table 44: Lannett Company Basic Information And Sales Area

Table 45: Lannett Company. Products Portfolio

Table 46: Apotex Basic Information And Sales Area

Table 47: Apotex. Products Portfolio

Table 48: Dr. Reddys Laboratories Basic Information And Sales Area

Table 49: Dr. Reddys Laboratories. Products Portfolio

Table 50: Aurobindo Pharma Basic Information And Sales Area

Table 51: Aurobindo Pharma. Products Portfolio

Table 52: Accord Healthcare Basic Information And Sales Area

Table 53: Accord Healthcare. Products Portfolio

Table 54: Hetero Basic Information And Sales Area

Table 55: Hetero. Products Portfolio

Table 56: Unimark Basic Information And Sales Area

Table 57: Unimark. Products Portfolio

Table 58: Ajanta Pharma Basic Information And Sales Area

Table 59: Ajanta Pharma. Products Portfolio

Table 60: MACLEODS Basic Information And Sales Area

Table 61: MACLEODS. Products Portfolio

Table 62: Jubilant Pharma Basic Information And Sales Area

Table 63: Jubilant Pharma. Products Portfolio

Table 64: Unichem Laboratories Basic Information And Sales Area

Table 65: Unichem Laboratories. Products Portfolio

Table 66: Amneal Pharmaceuticals Basic Information And Sales Area

Table 67: Amneal Pharmaceuticals. Products Portfolio

Table 68: Shanghai Anbison Lab Basic Information And Sales Area

Table 69: Shanghai Anbison Lab. Products Portfolio

Table 70: Perrigo Basic Information And Sales Area

Table 71: Perrigo. Products Portfolio

Table 72: Cipla Basic Information And Sales Area

Table 73: Cipla. Products Portfolio

Table 74: CSPC Ouyi Pharmaceutical Basic Information And Sales Area

Table 75: CSPC Ouyi Pharmaceutical. Products Portfolio

Table 76: Global Market Value (USD Million) (2025-2032) By Application

Table 77: Global Market Share (%) By Application (2032)

Table 78: Global Market Value (USD Million) (2025-2032) By Types

Table 79: Global Market Share (%) By Types (2032)

Table 80: Global Montelukast Drug Market Value (USD Million) By Region

Table 81: Global Montelukast Drug Market Share (%) By Region (2025-2032)

Table 82: North America Market Value (USD Million) (2025-2032) By Country

Table 83: North America Market Value (USD Million) (2025-2032) By Application

Table 84: North America Market Value (USD Million) (2025-2032) By Types

Table 85: Europe Market Value (USD Million) (2025-2032) By Country

Table 86: Europe Market Value (USD Million) (2025-2032) By Application

Table 87: Europe Market Value (USD Million) (2025-2032) By Types

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 90: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 91: South America Market Value (USD Million) (2025-2032) By Country

Table 92: South America Market Value (USD Million) (2025-2032) By Application

Table 93: South America Market Value (USD Million) (2025-2032) By Types

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 96: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 97: Research Programs/Design For This Report

Table 98: Key Data Information From Secondary Sources

Table 99: Key Data Information From Primary Sources

FAQs

1. What is the current Montelukast Drug market size?

The Montelukast Drug market size reached approximately USD 1.3 billion in 2023, reflecting steady demand across asthma and allergic rhinitis therapies. This valuation incorporates branded and generic sales across North America, Europe, and emerging Asian markets.

2. What is the projected growth rate and forecast for the Montelukast Drug market?

Analysts forecast the Montelukast Drug market to expand at a compound annual growth rate of 5.7 % from 2024 to 2032, reaching roughly USD 2.1 billion by the end of the forecast horizon, driven by expanding respiratory disease prevalence.

3. Which factors are driving growth in the Montelukast Drug market?

Key drivers include rising asthma incidence, increased awareness of leukotriene pathway therapies, growing pediatric prescriptions, and the shift toward oral fixed‑dose combinations that improve adherence. Additionally, expanding insurance coverage in emerging economies supports broader market penetration.

4. What challenges could hinder the Montelukast Drug market's expansion?

Challenges comprise safety concerns over neuropsychiatric events, competition from newer biologics, price erosion due to generic entry, and reimbursement restrictions in mature markets. Moreover, variable prescribing habits among clinicians can limit adoption of Montelukast in certain therapeutic lines.

5. Which regions are leading the Montelukast Drug market, and why?

North America remains the dominant region, accounting for over 45 % of global sales, thanks to robust healthcare infrastructure and high asthma prevalence. Europe follows, driven by strong reimbursement policies, while Asia‑Pacific shows rapid growth due to expanding middle‑class populations and increasing disease awareness.

6. Who are the top companies competing in the Montelukast Drug market?

Market leadership is shared by Merck & Co., which markets Singulair, and generic manufacturers such as Teva, Mylan, and Sun Pharma. Emerging biosimilar players are also entering, leveraging cost‑effective production to challenge incumbents in price‑sensitive segments and markets.

7. What future opportunities exist for the Montelukast Drug market?

The future outlook highlights opportunities in pediatric formulation upgrades, combination therapies with inhaled corticosteroids, and expansion into tele‑health prescribing platforms. Additionally, emerging markets present untapped patient pools, while digital adherence tools could boost long‑term usage rates.

8. How is technology influencing the Montelukast Drug market?

Advanced analytics enable manufacturers to predict demand spikes and optimize inventory, while AI‑driven drug‑delivery research is exploring novel oral‑disintegrating tablets. Remote monitoring apps also provide real‑time adherence data, informing physicians and shaping personalized treatment pathways.

9. What is the regulatory landscape affecting Montelukast Drug market growth?

Regulators in the US and EU have issued updated safety warnings on neuropsychiatric risks, prompting label revisions and post‑marketing surveillance. Simultaneously, accelerated generic pathways in India and China facilitate market entry, balancing safety oversight with opportunities to expand the Montelukast Drug market size.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Montelukast Drug Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	3.50 billion
Growth rate	CAGR of 4.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck & Co.; Teva; Mylan; Glenmark Pharmaceuticals; Hikma Group; Sandoz; Torrent Pharmaceuticals; Lannett Company; Apotex; Dr. Reddys Laboratories; Aurobindo Pharma; Accord Healthcare; Hetero; Unimark; Ajanta Pharma; MACLEODS; Jubilant Pharma; Unichem Laboratories; Amneal Pharmaceuticals; Shanghai Anbison Lab; Perrigo; Cipla; CSPC Ouyi Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options